Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.36 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.35 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.35 |
| ▸ | ADAM10 | O14672 | 1/20 | 0.35 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | MME | P08473 | 4/20 | 0.34 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.34 |
| ▸ | ACE | P12821 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27773432 | 0.78 | GAA (0.39) | GAAMAPTMTNR1A | |
| SCHEMBL3244858 | 0.73 | MAPT (0.46) | GAAMAPTMEN1KMT2ABLM | |
| SCHEMBL22231618 | 0.69 | GAA (0.62) | GAAMAPTMEN1KMT2ATSHR | |
| SCHEMBL16579321 | 0.69 | MEN1 (0.50) | MAPTMEN1KMT2ABLMTAAR1 | |
| SCHEMBL3242963 | 0.69 | MEN1 (0.46) | MAPTMEN1KMT2ABLMKEAP1 | |
| SCHEMBL30059612 | 0.69 | MAPT (0.53) | GAAMAPTMEN1KMT2ABLM | |
| SCHEMBL9294337 | 0.69 | GAA (0.81) | GAAMAPTTSHRNPSR1MME | |
| SCHEMBL18601145 | 0.68 | GAA (0.60) | GAAMAPTMEN1KMT2ATSHR | |
| SCHEMBL91080 | 0.67 | GAA (1.00) | GAAMAPTMMEACE | |
| SCHEMBL29495388 | 0.67 | GAA (1.00) | GAAMAPTMMEACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2102204-B1 | NEW AMINOPYRROLO[1,2- A]INDOLE ET AMINOPYRIDAZINO[1,6-A]INDOLE DERIVATIVES, METHOD FOR PREPARING THE SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | SERVIER LAB (FR) | 2010-05-05 | — | — | EP | disclosed |
| US-20090298813-A1 | USE OF NEUROPROTECTIVE COMPOUNDS IN OBTAINING MEDICAMENTS INTENDED FOR THE TREATMENT OF NEURODEGENERATING DISEASES | LES LABORATOIRES SERVIER (FR) | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298813-A1 | USE OF NEUROPROTECTIVE COMPOUNDS IN OBTAINING MEDICAMENTS INTENDED FOR THE TREATMENT OF NEURODEGENERATING DISEASES | NLN, GAP43, SNCA | GAA 139/4885MAPT 26/4885MEN1 3021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.